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Cetuximab is a standard-of-care treatment for RAS wild-type metastatic colorectal cancer (mCRC) but 
not for those harbor a KRAS mutation since MAPK pathway is constitutively activated. Nevertheless, 
cetuximab also exerts its effect by its immunomodulatory activity despite the presence of RAS 
mutation. The aim of this study was to determine the impact of polymorphism FcγRIIIa V158F and killer 
immunoglobulin-like receptor (KIR) genes on the outcome of mCRC patients with KRAS mutations 
treated with cetuximab. This multicenter Phase II clinical trial included 70 mCRC patients with KRAS 
mutated. We found KIR2DS4 gene was significantly associated with OS (HR 2.27; 95% CI, 1.08–4.77; 
p = 0.03). In non-functional receptor homozygotes the median OS was 2.6 months longer than in 
carriers of one copy of full receptor. Multivariate analysis confirmed KIR2DS4 as a favorable prognostic 
marker for OS (HR 6.71) in mCRC patients with KRAS mutation treated with cetuximab. These data 
support the potential therapeutic of cetuximab in KRAS mutated mCRC carrying non-functional 
receptor KIR2DS4 since these patients significantly prolong their OS even after heavily treatment. 
KIR2DS4 typing could be used as predictive marker for identifying RAS mutated patients that could 
benefit from combination approaches of anti-EGFR monoclonal antibodies and other immunotherapies 
to overcome the resistance mediated by mutation in RAS.
Colorectal cancer (CRC) is the third most common cancer worldwide and the second most common in Europe 
with 447,136 new cases in 20121. Specifically in Spain the incidence was 32,240 new cases. If trends continue by 
December 31, 2020, Spain will have approximately 37,229 new CRC cases2. Approximately 20% of patients pres-
ent metastatic disease (mCRC) at diagnosis3.
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Deregulation of the mitogen-activated protein kinase pathway is required for the development of CRC and 
it is activated by binding of growth factor ligands to the epidermal growth factor receptor (EGFR)4. Cetuximab 
is a monoclonal antibody that binds to the extracellular domain of EGFR, causing inhibition of the downstream 
signaling pathway, and is a widely used biological treatment for mCRC5. Mutations in KRAS result in constitutive 
activation of the pathway, since it is expected that patients with mutations in KRAS will not benefit from cetuxi-
mab treatment6. Despite this rationale, approximately 30% of mCRC patients with mutations in KRAS do benefit 
from cetuximab7. Understanding the mechanisms underlying the response of this subgroup to cetuximab could 
benefit these hard-to-treat patients.
Because cetuximab is an IgG1 monoclonal antibody it also exerts its effect by its immunomodulatory activity 
in part via antibody-dependent cell-mediated cytotoxicity (ADCC)8–10. Cetuximab stimulates ADCC activity 
when its constant region (Fc) binds to a Natural Killer (NK) cell receptor (CD16/FcγRIIIa) leading their own 
lytic activity on tumor cells9,11. Also important downstream immunological responses are possible when CD32A/ 
FcγRIIa receptors are present on dendritic cells and neutrophils leading to priming of tumor antigen-specific 
cellular immunity12. Previous reports suggested that specific polymorphic variants of FcγR are associated with 
the clinical outcome of cancer patients13,14. In particular, the FcγRIIa H131 allele has been shown to increase 
the ability of cetuximab to control disease in patients with mutated KRAS8. The role of FcγRIIIa in the ADCC 
induction by cetuximab in colorectal cancer patients is controversial. While in one study no statistically signifi-
cant associations between the presence of FcγRIIIa and response, progression-free survival (PFS) or RAS status 
in mCRC patients were found15, in a subsequent study a tendency for a higher disease control rate (DCR) was 
shown in patients with the FcγRIIIa V-containing genotype8. Recently, a different study demonstrated that the 
FcγRIIIa V158V genotype was correlated with a higher ADCC16, although sample size was too small to confirm 
the impact of this association.
A clinical trial with KRAS wt mCRC patients treated with cetuximab + Irinotecan showed that ADCC 
response was not affected by BRAF or NRAS mutations17. Another phase III clinical trial with very similar 
patients demonstrated that ADCC response scores were higher in patients carrying FcγRIIa 131H allele vs. 131R/
R18. Furthermore, FcγRIIIa 158V carriers were associated with higher cetuximab-mediated ADCC compared to 
158F/F. Objective response was significantly higher in both patients carrying the FcγRIIa 131H allele and those 
carrying the FcγRIIIa 158V allele. However, survival analysis only revealed longer progression-free survival in 
patients carrying FcγRIIIa 158V allele18.
Besides FcγRIIIa, Killer immunoglobulin-like receptors (KIRs) are also essential in the immune response 
against tumor cells17,18. They are located on the surface of NK cells and regulate their killing function in the ADCC 
response19. To date, 14 functional KIR genes and two pseudogenes located in the leukocyte receptor complex on 
chromosome 19q13.4 have been identified. They present a very high degree of structural homology and can be 
classified as inhibitors or activators of the immune response depending on their cytoplasmic tails. Products of 
inhibitory KIR genes are characterized by long cytoplasmic tails (“L” KIR genes) and transmit inhibitory signals 
leading to the general shutdown of NK cell effector functions. Opposite, activating KIR proteins have short cyto-
plasmic tails (“S” KIR genes) and their signal promotes NK cell activity20. The immune-modulating effects depend 
on the balance of the number and type of receptors exposed on the cell surface21. KIR genes are organized in a 
highly polymorphic multigene family and their combination define two main groups of haplotypes. A haplotypes 
are characterized by a predominance of genes encoding inhibitory receptors. B haplotypes are more heterogeneous 
and generally contain several activating genes22. A recent study provides evidence of the role of specific variants of 
KIRs on the response to anti-EGFR treatment in solid tumors including RAS wild type advanced colorectal cancer. 
Due to the strong immunomodulatory activity of cetuximab we hypothesized that both KIR and FcγRIIIa receptors 
might influence the response of mCRC patients to cetuximab independently of RAS mutation.
This prospective multicenter clinical study aimed to determine whether polymorphisms in CD16/FcγRIIIa 
and/or KIR genes could enhance the clinical impact of the FcγRIIa polymorphism in mCRC patients with KRAS 
mutated who are treated with cetuximab.
Results
Patient characteristics and clinical outcome. Table 1 summarizes the baseline demographic and dis-
ease characteristics of the participants. Baseline blood levels were: median 46.50 ng/μL (0–2930) for CEA, median 
330 UI/L (150–5882) for LDH and 2.10 mg/L (1–4) for β2-microglobulin. The median time of follow-up was 6.4 
months (range: 3.8–10.2 months).
Overall, 68 patients (97.1%) experienced disease progression. Fifty-six (80.0%) patients died during the study 
period.
Median OS was 6.71 months with a 95% CI of (5.4–8.1) and median PFS was 2.53 with a 95% CI of (2.4–2.7).
Frequency of V158F FcγRIIIa allele and presence of KIR genes. Twenty-eight out of 70 patients 
(39.4%) were homozygous for FcγRIIIa-158F allele, 36 patients (52.1%) were heterozygous (V/F) and 6 (8.5%) 
were homozygous for FcγRIIIa-158V allele (Table 2). The minor allele frequency of this polymorphism was 34% 
in our series, which was in concordance with the frequency described in the Spanish population23.
With regard to KIR genes (Table 2), some of the gene variants were present in more than 90% of the patients 
(KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3 and KIR2DP1). Owing to this high frequency, 
these genes were excluded from the survival analysis. The remaining KIR genes and pseudogene (KIR3DP1) were 
included in the survival analysis.
Survival analysis. Regarding clinical and biochemical parameters only the number of metastatic sites was 
significantly correlated by univariate analysis (Table 3).
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Cox regression analysis showed that only KIR2DS4 polymorphism was significantly associated with OS 
(Table 4). KIR2DS4 encodes two different proteins, a full length variant (KIR2DS4f) and a truncated protein with 
a 22-bp deletion in exon 5 (KIR2DS4d) resulting in a protein unable to attach to the cytoplasmic membrane. 
The genotype distribution in the study population was 50 (71.4%) homozygotes for the KIR2DS4d, four (5.7%) 
homozygotes for the KIR2DS4f, 10 (14.28%) heterozygotes (f/d) and six (8.6%) patients did not have any copy 
of the KIR2DS4 gene. As both homozygotes for the deleted variant and patients with no copy of the gene have a 
non-functional receptor (NFR), these patients were grouped together. A significantly lower OS was observed for 
patients with at least one KIR2DS4f allele compared with individuals without a functional receptor (median 4.8 
months vs. 7.4 months; HR 2.27; 95% CI, 1.08–4.77; P = 0.026) (Fig. 1). Since the number of homozygotes for 
KIR2DS4f was very small (n = 4), it was not possible to determine the expected cumulative effect of this genotype.
Multivariate logistic regression model, adjusted for baseline characteristics, showed that 3 or more metastatic 
sites and KIR2DS4 polymorphism were independent predictors of overall survival (OS) in KRAS mutated mCRC 
patients carrying FcγRIIa H131 allele and receiving cetuximab (HR 3.03, P = 0.007 and HR 2.17, P = 0.045, 
respectively) (Table 5).
Logistic regression and disease control rate (DCR) analysis were also performed; however, no significant result 
was obtained (data not shown).
Discussion
Our results support with new evidences the immunomodulatory activity of cetuximab in mCRC patients regard-
less KRAS status. In particular, subjects carrying the non-functional receptor KIR2DS4 showed longer OS than 
carriers of the full-length variant.
We have previously described higher disease control rate (DCR) in KRAS mutated patients carrying FcγRIIa 
H131 allele; however, only a tendency was observed for patients with the FcγRIIIa V-containing genotype. 
Although this polymorphism is the best-studied biomarker for ADCC its clinical value is not fully confirmed. An 
analysis in head and neck squamous cell carcinoma, no predictive value for FcγRIIIa F158V polymorphism was 
detected for cetuximab efficacy24; and a study in refractory mCRC patients treated with anti-EGFR antibodies did 
not found significant associations between FcγRIIIa polymorphism and clinical outcome15. However, two differ-
ent studies in mCRC patients with KRAS wild-type found a significant difference in outcomes among patients 
carrying different genotypes of this polymorphism18,25. We have evaluated this polymorphism in our cohort of 
Patients (N = 70)
Age at diagnosis (years)







Number of metastatic sites
1 16 (22.8)
2 27 (38.6)

















Table 1. Baseline characteristics of patients. Abbreviations: CEA, carcinoembryonic antigen; ECOG, Eastern 
Cooperative Oncology Group; LDH, lactate dehydrogenase; N/A, Not available; ULN, Upper limit of the 
normal range.
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KRAS mutated mCRC patients treated with cetuximab, similarly to Paez et al.15 we have observed no effect of 
FcγRIIIa V158F on OS or PFS.
Despite the central role of NK-cells in ADCC and the essential role of KIR receptors to modulate NK cell 
function, the impact of the KIRs on the mCRC clinical outcome have been essentially unexplored. A recent study 
demonstrated the use of genotyping KIR to predict overall survival to treatment with FOLFIRI in mCRC patients. 
The authors showed the absence of KIR2DS4 and 3DL1 increased complete response26. Apart from this study, 
there are few more analyses assessing the clinical impact of KIRs in cancer. Siebert et al.27 found higher level of 
ADCC and superior event-free survival in Neuroblastoma patients with haplotype B (combination of KIR genes 
including activating receptor genes) compared to inhibitory haplotype A (a fixed set of gene encoding for inhibi-
tory receptors, except 2DS4). Also in Neuroblastoma patients, Forlenza et al.28 evaluated whether combinations of 
KIR3DL1 and HLA ligands could influence patient outcome after treatment with anti-GD2 monoclonal antibody. 
They evaluated a total of 245 patients and found that single KIR3DL1 did not impact survival but after assessing 
combinations of KIR3DL1 and HLA-B they found that when receptor and ligand did not interact at the cell surface 
exhibited the greatest OS and PFS. Similar results were observed by Boudreau et al.29 when investigated the impact 
of KIR3DL1/HLA-B combinations in 1,328 patients with acute myelogenous leukemia who underwent hematopoi-
etic cell transplantation (HCT). Patients with weak or non-inhibiting KIR3DL1/HLA-B partnership experienced 
higher DFS after HCT. Recently, it has been published other study in patients with chronic myeloid leukemia 
treated with tyrosine kinase inhibitors (TKIs)30. The authors hypothesized that KIR and HLA polymorphisms 
may influence response to TKIs. They did not find association between single KIR genes or the presence of a single 
functional combination of an inhibitory KIR-HLA genotype with achievement of complete molecular response. 
However, specific alleles of KIR2DL4, KIR3DL1 and KIR2DS4 were associated with response. A study in non-small 
cell lung cancer showed patients with absence of KIR2DS4 had longer OS than patients who were positive31. A 
third study demonstrated that donor’s full-length KIR2DS4 allele is associated with lower OS rates and higher 
relapse incidence in patients with hematological malignancies32. Finally, a very recently study showed a protective 
impact of deleted KIR2DS4 on genetic predisposition to head and neck squamous cell carcinoma (HNSCC)33.
In our study, a significant survival advantage was observed for patients without functional KIR2DS4, sug-
gesting a novel favorable and independent prognostic biomarker for overall survival in mCRC patients KRAS 
mutated and treated with cetuximab. KIR2DS4 encodes two different allele variants, full-length (KIR2DS4f) 
or deleted (KIR2DS4d). A deleted KIR2DS4 is a truncated protein without transmembrane and cytoplasmic 
domains compared to full-length KIR2DS4 protein. Therefore, this truncated protein is not anchored to cell 
membrane becoming a soluble variant21. The role of this soluble protein remains unclear but it has been suggested 
that the presence of this truncated protein could minimize the detrimental effects of the KIR2DS4f 33. Its function 
Polymorphic gene Genotype frequency N (%)
FcγRIIIa FF FV VV
V158 F 28 (40) 36 (51.4) 6 (8.6)
Inhibitory KIR genes + −
2DL1 64 (91.4) 6 (8.6)
2DL2 37 (52.9) 33 (47.1)
2DL3 63 (90.0) 7 (10.0)
2DL4a 70 (100) —
2DL5A 28 (40.0) 42 (60.0)
2DL5B 20 (28.6) 50 (71.4)
3DL1 64 (91.4) 6 (8.6)
3DL2 70 (100) —
3DL3 70 (100) —
Activating KIR genes + −
2DS1 37 (52.9) 33 (47.1)
2DS2 36 (51.4) 34 (48.6)
2DS3* 30 (43.5) 39 (56.5)
2DS4f 14 (20.0) 56 (80.0)
2DS4d 60 (85.7) 10 (14.2)
2DS5 22 (31.4) 48 (68.5)
2DL4a 70 (100) —
3DS1 28 (40.0) 42 (60.0)
KIR pseudogenes + −
2DP1 64 (91.4) 6 (8.6)
3DP1f 20 (28.6) 50 (71.4)
3DP1d 50 (71.4) 20 (28.6)
Table 2. Polymorphisms frequencies. *One patient was undetermined; aIt has both properties. Abbreviations: d, 
deleted variant; f, full variant.
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could potentially be a decoy that absorbs the available soluble HLA and thus potentially interferes with NK cell 
function or may be related to an alternative receptor ligand34,35. It is important to highlight that KIR2DS4 is the 
only activating gene within the KIR A haplotype. Therefore individuals with haplotype A being homozygous for 
the deleted KIR2DS4 will carry only inhibiting KIRs which has been associated with a protective role against 
some types of cancer such as HNSCC33. Based on our results and those of the above-mentioned studies, we can 
assume that the lack of functional KIR2DS4 has a positive impact on clinical outcome of cancer patients treated 
with anti-IgG1 therapies. In our cohort, this influence is stronger when NFR-KIR2DS4 and FcγRIIa H131 allele 
are combined, this effect was also observed in neuroblastoma patients treated with anti-GD2 IgG1 Ab27.
An important factor to consider was the possibility that patients with the G13D mutation skewed our analysis. 
However, we found no significant differences in OS (P = 0.22) or PFS (P = 0.70) in G13D patients compared to 
the rest of patients. It is in agreement with Segelov et al.36 who did not find statistically significant improvement 
in disease control at 6 months in patients with G13D mutation chemotherapy-refractory mCRC treated with 
cetuximab.
One of the limitations of our study that warrant consideration is that it has been performed in a limited 
cohort. To address whether the combination of FcγRIIa and KIR2DS4 could be a suitable predictive marker for 
KRAS mutated patients, it should be confirmed in large-scale prospective studies.
In conclusion, the use of FcγRIIa H131R and KIR2DS4 to identify the subset of KRAS mutated patients who 
might benefit from cetuximab therapy could improve the current management strategies available for these 
patients. Moreover, these results could explain the observed variability in efficacy of cetuximab in KRAS mutated 
mCRC patients and confirm the important role of ADCC-mediated toxicity to tumor cells by cetuximab.
Methods
Patients and trial design. From September 2011 through December 2013, 70 mCRC patients with 
KRAS mutations were prospectively enrolled in this multicenter Phase II clinical trial (registration number: 
NCT01450319, 07/10/2011; EudraCT Number: 2010-023580-18). Sample size was calculated using a one-sided 
test with a significance level of α = 0.05, assuming a recruitment period of 14 months and 12 months of follow-up 
Overall survival Progression-free survival
P HR (95% CI) P HR (95% CI)
Sex (female vs. male) 0.568 1.17 (0.69–1.98) 0.549 1.17 (0.71–1.92)
Age (≥60 vs. <60) 0.824 0.94 (0.51–1.70) 0.335 1.30 (0.76–2.22)
Tumor primary site (rectum vs. colon) 0.687 1.13 (0.63–2.04) 0.466 1.24 (0.70–2.18)
ECOG (1 & 2 vs. 0) 0.384 1.38 (0.67–2.821) 0.630 1.16 (0.63–2.15)
CEA (>ULN vs. ≤ULN) 0.376 1.47 (0.63–3.45) 0.288 1.54 (0.70–3.40)
LDH (>ULN vs. ≤ULN) 0.465 1.23 (0.71–2.15) 0.520 1.18 (0.71–1.98)
β2 microglobulin (>ULN vs. ≤ULN) 0.678 0.85 (0.40–1.83) 0.767 0.89 (0.42–1.90)
Number of metastatic sites
2 vs. 1 0.069 2.00 (0.95–4.22) 0.172 1.61 (0.81–3.18)
3 or more vs. 1 0.009 2.75 (1.28–5.89) 0.007 2.53 (1.29–4.97)
Table 3. Cox regression univariate analysis for the association between baseline characteristics and patients’ 
outcome. Abbreviations: CEA, carcinoembryonic antigen; CI, confidence interval; ECOG, Eastern Cooperative 
Oncology Group; HR, Hazard ratio; LDH, lactate dehydrogenase; ULN, Upper limit of the normal range.
Overall survival Time to progression
P HR (95% CI) P HR (95% CI)
FcγRIIIa V158F* 0.864 1.05 (0.61–1.79) 0.363 0.79 (0.48–1.31)
KIR2DL2 0.909 1.03 (0.60–1.76) 0.444 0.83 (0.50–1.35)
KIR2DL5A 0.934 1.02 (0.60–1.76) 0.754 0.92 (0.55–1.54)
KIR2DL5B 0.880 0.96 (0.53–1.73) 0.209 0.70 (0.40–1.22)
KIR2DS1 0.776 1.08 (0.63–1.86) 0.888 0.97 (0.59–1.58)
KIR2DS2 0.967 0.99 (0.58–1.69) 0.349 0.79 (0.48–1.29)
KIR2DS3 0.587 1.16 (0.68–1.97) 0.292 0.76 (0.46–1.26)
KIR2DS4† 0.030 2.25 (1.08–4.71) 0.496 1.28 (0.63–2.64)
KIR3DS1 0.520 1.19 (0.70–2.05) 1.000 1.00 (0.60–1.67)
KIR3DP1¥ 0.888 1.04 (0.59–1.85) 0.562 1.18 (0.67–2.07)
Table 4. Cox regression univariate analysis for the association between polymorphisms in KIR genes or 
FcγRIIIa and outcome of the patients. *Individuals with at least one valine (FV and VV) were compared with 
homozygous for phenylalanine (FF). †Carriers of one full variant (KIR2DS4f/d) were compared to individuals 
with no functional receptor (NFR). ¥Individual carrying at least one full variant. Abbreviations: CI, confidence 
interval; HR, Hazard ratio.
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and considering a minimum frequency of 30% for the KIR and FcγRIIIa-F158V polymorphisms. In order to 
detect an improvement of overall survival compared to historical controls with at least 80% power, it was esti-
mated a sample size of 70 patients assuming an exponential distribution for OS, a one-sided null hypothesis H0: 
Median OS <= 5 months and, an actual median OS of 7 months. Primary endpoint was OS, and the secondary 
endpoint was progression-free survival.
This study was approved by the Institutional Ethical Committee at the University Hospital Fundacion Jimenez 
Diaz (authorization number EC 02-12 IIS-FJD) and accepted by the other 12 participating hospitals located across 
Spain. All of them were general hospitals and publically funded excepting “Clínica Universitaria of Navarra” that 
was private. Written informed consent was obtained from all patients before enrollment. All methods were car-
ried out in accordance with the approved guidelines and regulations.
The patients included in this study were eligible taking into account the inclusion criteria: (A) histologically 
confirmed mCRC with confirmed KRAS mutation; (B) positive EGFR expression; (C) carrier of at least one his-
tidine at position 131 in FcγRIIa; (D) aged 18 years or older; (E) Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–2. All patients had adequate bone marrow, renal and liver functions and were refractory 
to at least two lines of treatment including standard chemotherapy.
Major exclusion criteria were previous anti-EGFR monoclonal antibody-based therapy, presence of brain 
metastases or evidence of toxicity greater than grade 1 caused by previous treatment.
After enrollment, cetuximab was administered as an intravenous dose of 500 mg/m2 of body surface area, 
every two weeks until unacceptable toxicity, disease progression, death or revocation of the informed consent.
Baseline measurements. Peripheral blood was collected in 5-ml tubes with EDTA. Blood levels of carci-
noembryonic antigen (CEA), lactate dehydrogenase (LDH) and β2-microglobulin levels were evaluated before 
Figure 1. Kaplan–Meier curve for overall survival according to the status of the KIR2DS4 gene. Heterozygous 
individuals (full variant [f] and deleted variant [d]; f/d) were compared with all patients with the non-functional 
receptor (homozygous deleted variant and without any copy of the gene; NFR). All patients were carriers of 
FcγRIIa H131 polymorphism. The median overall survival among heterozygotes for the KIR2DS4f allele was 
4.8 months (95% CI, 3.45–6.08) and 7.4 months (95% CI, 5.97–8.82) for patients with NFR (P = 0.026; log-rank 
test).
Overall survival
P HR (95% CI)
Number of metastatic sites
2 vs. 1 0.085 2.02 (0.91–4.49)
3 or more vs. 1 0.007 3.03 (1.36–6.76)
KIR2DS4† 0.045 2.17 (1.02–4.63)
Table 5. Cox regression multivariate analysis for overall survival. †Carriers of one full variant (KIR2DS4f/d) 
were compared to individuals with no functional receptor (NFR). Abbreviations: CI, confidence interval; d, 
deleted variant; f, full variant; HR, Hazard ratio; NFR, non-functional receptor.
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initiation of cetuximab therapy as they have been described as prognostic factors in colorectal cancer37–39. Patients 
were grouped according to the upper limit of the normal range (ULN) for each measure (>5 mcg/L for CEA, 333 
UI/L for LDH and 3 mg/L for β2-microglobulin).
FcγRIIIa V158F polymorphism and KIRs genotyping. Genomic DNA extraction was performed using 
the QIAamp DNA Blood Mini Kit (Qiagen). The purified DNA was quantified with a NanoDrop 3.0 spectropho-
tometer (Nucliber).
The FcγRIIIa genotype was determined using the TaqMan Allelic Discrimination Assay (assay code 
C_25815666_10, Applied Biosystems) according to the manufacturer’s instructions. After thermal cycling, allelic 
determination was performed using the 7500 Fast real-time PCR instrument (Applied Biosystems). Samples of 
known genotype were included as the positive control.
The 17 KIR genes were determined using the KIR genotyping SSP Kit (Applied Biosystems) according to the 
manufacturer’s protocol. After thermal cycling the genotype-specific PCR products were resolved using 2% aga-
rose gels and interpreted according to the manufacturer’s instructions.
Statistical Methods. Overall survival was defined as the time from enrollment until death from any cause. 
Progression-free survival was calculated as the time from enrollment until disease progression, or death due to 
any cause. In the absence of confirmation of disease progression or death, the participant was censored at the 
last contact, known to be alive and progression free. Those patients who started a new treatment (different from 
cetuximab) were censored at the date of starting the new treatment.
Univariate analysis was performed to assess the effect of genetic markers and clinical variables on the predic-
tion of outcome. Only variables that were statistically significant by univariate analysis were considered as covar-
iates in the multivariate Cox regression model. The survival probability was estimated using the Kaplan-Meier 
method, and the log-rank test was used to test the differences between the subgroups.
Data analysis was performed using the SPSS statistics version 20.0 software package.
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